Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Voyager Therapeutics’ stock jumps 57% following Pfizer licensing deal

By Brian Buntz | October 6, 2021

Voyager Therapeutics/PfizerThe gene therapy company Voyager Therapeutics, Inc. (NSDQ: VYGR) has reached an agreement with Pfizer (NYSE:PFE) to license novel capsids from its RNA-driven TRACER screening technology.

A capsid refers to the protein shell of a virus protecting its genome.

“We believe that our TRACER platform has the ability to produce not only enhanced blood-brain-barrier penetrant capsids, but also novel capsids with enhanced tropisms across a diversity of tissues and cell types, offering promise to unlock the fullest potential of gene therapies for a wide array of diseases with unmet medical need,” Michael Higgins, Interim CEO of Voyager said in a statement.

TRACER is an acronym for Tropism Redirection of AAV by Cell-type-specific Expression of RNA. AAV is an abbreviation of adeno-associated viruses.

VYGR shares jumped 56.7% apiece to $3.87 on the heels of the announcement.

In the past 12 months, the company’s stock had gradually fallen from $11.90 on October 8, 2020, to $2.56 on October 4, 2021.

Under the terms of the agreement, Voyager will receive an initial $30 million upfront payment. It could receive an additional $20 million if Pfizer chooses to exercise two options within 12 months of signing the agreement. In addition, Voyager could receive up to $580 million in additional development, regulatory and commercial milestones. It could also receive royalty payments based on net sales of Pfizer products using Voyager-licensed capsids.

Pfizer reportedly plans to use the novel capsids for gene therapies using two undisclosed transgenes to treat neurologic and cardiovascular conditions.


Filed Under: Cardiovascular, Drug Discovery, Drug Discovery and Development, Neurological Disease
Tagged With: Pfizer, RNA, TRACER, Voyager Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50